Researchers investigated whether a high-refined carbohydrate diet and associated metabolic alterations could cause small intestinal dysregulation.
Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer
In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab